Tecovirimat SIGA 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
S/0004 
Annual re-assessment. 
12/10/2023 
07/12/2023 
Annex II 
The CHMP, having reviewed the evidence of compliance 
with the specific obligations and the impact of the data 
submitted by the MAH on the benefit/risk profile of the 
medicinal product, concluded that marketing authorisation 
of Tecovirimat SIGA should be varied, updating Annex II 
with a new specific obligation: “To ensure adequate 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
monitoring of safety and efficacy of Tecovirimat in the 
treatment of the Smallpox, Mpox, Cowpox viral infections 
and complications due to replication of vaccinia virus 
following vaccination against smallpox in adults and 
children with body weight at least 13 kg, the MAH shall 
provide yearly updates on any new information concerning 
the safety and efficacy of tecovirimat.” 
II/0006 
C.I.11.b - Introduction of, or change(s) to, the 
12/10/2023 
07/12/2023 
Annex II 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
PSUSA/10971
Periodic Safety Update EU Single assessment - 
31/08/2023 
n/a 
PRAC Recommendation - maintenance 
/202301 
tecovirimat 
II/0005 
Update of section 4.2 of the SmPC in order to 
26/04/2023 
31/05/2023 
SmPC and PL 
As a result of this variation, sections 4.1, 4.2 and 5.1 of the 
introduce a new posology regimen for those with a 
body weight of 120 kg and above based on final 
results from study SIGA-246-022 and study report 
865, which is a PopPK modelling and simulation 
report. Study SIGA-246-022 is a multiple-dose, 
open-label, safety, tolerability, and pharmacokinetic 
study of tecovirimat in adults weighing more than 
120 kg. The Package Leaflet has been updated 
accordingly. In addition, the MAH took the 
opportunity to introduce minor editorial changes to 
the PI. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
SmPC are being updated to add the new posology and to 
change monkeypox to mpox. 
For more information, please refer to the Summary of 
Product Characteristics. 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
new quality, preclinical, clinical or pharmacovigilance 
data 
II/0003/G 
This was an application for a group of variations. 
16/03/2023 
n/a 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
IB/0007 
B.II.a.3.z - Changes in the composition (excipients) 
15/03/2023 
31/05/2023 
SmPC 
of the finished product - Other variation 
PSUSA/10971
Periodic Safety Update EU Single assessment - 
09/02/2023 
n/a 
PRAC Recommendation - maintenance 
/202207 
tecovirimat 
IB/0001 
The RMP has been updated to include follow up 
20/07/2022 
n/a 
The RMP has been updated to include follow up forms and 
forms and communication for prescribers (DHPC) for 
use in pregnancy and lactation and use in 
immunocompromised subjects in line with the 
communication for prescribers (DHPC) for use in pregnancy 
and lactation and use in immunocompromised subjects in 
line with the agency request in the D195 JAR. 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
agency request in the D195 JAR. 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
Page 4/4 
 
 
 
 
 
 
 
 
